GHK-Cu dosage has no approved human label to lean on.
A dosage search usually means you want a clear answer. With GHK-Cu, the missing human information matters more than a neat-looking number.
There isn't an approved schedule
GHK-Cu has no FDA-approved medicine label giving a human dose or schedule. That gap isn't filled by an online routine. FDA describes how little human safety information injections have. It also flags a possible immune response, with clumping or peptide impurities among the reasons for concern.
There is no FDA-approved GHK-Cu schedule to use as a starting point. An amount can look precise even when the evidence behind it is missing. The useful question is what supports the proposed use in people. A schedule without that answer gives you a number, but little reason to trust it.
A study amount stays with its study
Take the human hair trial. It tested a scalp mixture of free GHK and another ingredient, 5-aminolevulinic acid. That's a different preparation, applied a different way. Its amounts can't be borrowed for a GHK-Cu injection just because part of the name is familiar.
The same problem applies to cell and animal work. A concentration surrounding cells in a dish isn't an amount circulating in a person. Even matching the units doesn't fix that mismatch. The material, the species and the route all belong in the comparison before any arithmetic begins.
A precise number can't rescue the wrong comparison.
Half-life doesn't give us a timetable
A half-life measures the time for something's amount to drop to half its starting level under specified conditions. It isn't one clock shared by every form of a peptide. A PubMed search on September 30, 2026 found no human study measuring how GHK or GHK-Cu moves through and leaves the body. That search has limits; it cannot account for unpublished work.
In a rat experiment using free GHK, researchers gave it into a vein and saw it break down quickly. That's useful information about rats and GHK without copper. It doesn't establish a human GHK-Cu half-life. It also can't tell a person how far apart to space injections.
Questions that get closer to the issue
What human evidence supports the intended goal? What exactly is in the proposed preparation, and how would it be given? What remains unknown about safety? How would the clinician decide to continue, change or decline treatment?
A prescriber needs to consider the person as well as the evidence and care restrictions. A page can't do that review. The care chapter explains the regulatory limits, while FDA's compounding explanation makes clear that compounded medicines lack its approval. Prescribing doesn't close the research gap.